{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:33:55Z","timestamp":1772109235656,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Some reports suggest that acromegaly in elderly patients has a more benign clinical behavior and could have a better response to first-generation long-acting somatostatin receptor ligands (SRL). However, there is no specific therapeutic protocol for this special subgroup of patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed at identifying predictors of response to SRL in elderly patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Multicentric retrospective nationwide study of patients diagnosed with acromegaly at or over the age of 65 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One-hundred and eighteen patients (34 men, 84 women, mean age at diagnosis 71.7 \u00b1 5.4 years old) were included. Basal insulin-like growth factor type 1 (IGF-1) above the upper limit of normal (ULN) and growth hormone (GH) levels (mean \u00b1 SD) were 2.7 \u00b1 1.4 and 11.0 \u00b1 11.9 ng\/ml, respectively. The mean maximal tumor diameter was 12.3 \u00b1 6.4\u00a0mm, and up to 68.6% were macroadenoma. Seventy-two out of 118 patients (61.0%) underwent surgery as primary treatment. One-third of patients required first-line medical treatment due to a rejection of surgical treatment or non-suitability because of high surgical risk. After first-line surgery, 45\/72 (63.9%) were in disease remission, and 16\/34 (46.7%) of those treated with SRL had controlled disease. Patients with basal GH at diagnosis \u22646 ng\/ml had lower IGF-1 levels and had smaller tumors, and more patients in this group reached control with SRL (72.7% vs. 33.3%; p &amp;lt; 0.04) [OR: 21.3, IC: 95% (2.4\u201391.1)], while male patients had a worse response [OR: 0.09, IC 95% (0.01\u20130.75)]. The predictive model curve obtained for SRL response showed an AUC of 0.82 CI (0.71\u20130.94).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The most frequent phenotype in newly diagnosed acromegaly in the elderly includes small adenomas and moderately high IGF-1 levels. GH at diagnosis \u22646 ng\/ml and female gender, but not age <jats:italic>per se<\/jats:italic>, were associated with a greater chance of response to SRL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.984877","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T09:42:14Z","timestamp":1663321334000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain"],"prefix":"10.3389","volume":"13","author":[{"given":"Betina","family":"Biagetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Villar-Taibo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda-Dolores","family":"Moure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Paja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Ares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"\u00c1lvarez-Escola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c8lia","family":"\u00c1lvarez Guivernau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iria","family":"Novoa-Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Guerrero Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Lecumberri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Garc\u00eda G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Bernab\u00e9u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Manj\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Gaztambide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cordido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edelmiro Luis","family":"Men\u00e9ndez-Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Sim\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2020.1749048","article-title":"Potential markers of disease behavior in acromegaly and gigantism","volume":"15","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.23736\/S0391-1977.18.02937-1","article-title":"Precision medicine in the treatment of acromegaly","volume":"44","author":"Puig-Domingo","year":"2019","journal-title":"Minerva Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-08-0243","article-title":"The influence of age on the GH-IGF1 axis in patients with acromegaly","volume":"159","author":"Tanimoto","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: An endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: An update","volume":"105","author":"Giustina","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: A consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-020-00235-5","article-title":"Clinical presentation and management of acromegaly in elderly patients","volume":"20","author":"Ceccato","year":"2020","journal-title":"Hormones (Athens)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"Burton","year":"2016","journal-title":"Pituitary"},{"key":"B12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/BF03346334","article-title":"A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients","volume":"30","author":"Colao","year":"2007","journal-title":"J Endocrinol Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1507\/endocrj.k08e-117","article-title":"Treatment of elderly acromegalics","volume":"55","author":"Arita","year":"2008","journal-title":"Endocr J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s12020-020-02206-7","article-title":"Acromegaly in the elderly patients","volume":"68","author":"Ambrosio","year":"2020","journal-title":"Endocrine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12877-021-02549-4","article-title":"Multidimensional geriatric evaluation in acromegaly: A comparative cross-sectional study","volume":"21","author":"Gagliardi","year":"2021","journal-title":"BMC Geriatr"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the li\u00e8ge acromegaly survey (LAS) database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: A nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1210\/jc.2016-1937","article-title":"The Mexican acromegaly registry: Clinical and biochemical characteristics at diagnosis and therapeutic outcomes","volume":"101","author":"Portocarrero-Ortiz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro espanol de acromegalia, REA)","volume":"151","author":"Mestron","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2020-001605","article-title":"Incidentally detected acromegaly: single-center study of surgically treated patients over 22 years","volume":"69","author":"Giraldi","year":"2021","journal-title":"J Investig Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish acromegaly registry (REA)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.06.165","article-title":"Transsphenoidal surgery for elderly patients with acromegaly and its outcomes: Comparison with younger patients","volume":"118","author":"Sasagawa","year":"2018","journal-title":"World Neurosurg"},{"key":"B25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1227\/00006123-199504000-00006","article-title":"Pituitary surgery in elderly patients with acromegaly","volume":"36","author":"Puchner","year":"1995","journal-title":"Neurosurgery"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s007010100015","article-title":"Surgical treatment and clinical outcome of GH-secreting adenomas in elderly patients","volume":"143","author":"Minniti","year":"2001","journal-title":"Acta Neurochir (Wien)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1992.tb02304.x","article-title":"The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex","volume":"37","author":"van der Lely","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab069","article-title":"Predictors for remission after transsphenoidal surgery in acromegaly: A Dutch multicenter study","volume":"106","author":"Coopmans","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4158\/EP14587.OR","article-title":"SIGNIFICANT ELEVATION OF GROWTH HORMONE LEVEL IMPACTS SURGICAL OUTCOMES IN ACROMEGALY","volume":"21","author":"Anthony","year":"2015","journal-title":"Endocr Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03626.x","article-title":"Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006; acromegaly remains under-recognized and under-diagnosed","volume":"72","author":"Reid","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01113","article-title":"Prevalence, clinical and biochemical spectrum, and treatment outcome of acromegaly with normal basal GH at diagnosis","volume":"103","author":"Espinosa de Los Monteros","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0735-0","article-title":"\u201cMicromegaly\u201d: An update on the prevalence of acromegaly with apparently normal GH secretion in the modern era","volume":"19","author":"Butz","year":"2016","journal-title":"Pituitary"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.8.8658","article-title":"Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up","volume":"87","author":"Dimaraki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: Post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: A real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.984877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T09:42:17Z","timestamp":1663321337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.984877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":36,"alternative-id":["10.3389\/fendo.2022.984877"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.984877","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"article-number":"984877"}}